*To the Editor*:

A recent series in the *Journal* by Ziehr and colleagues ([@bib1]) details their institutional experience with 66 mechanically ventilated patients with coronavirus disease (COVID-19) in the ICU. Acknowledging differences in outcome definitions and length of follow up, the strikingly low mortality rate of 16.7% reported by these authors still stands in stark contrast to data for such patients from around the world, so much so that this mortality figure resembles survival figures from other sites ([@bib2]--[@bib4]). This number is also at odds with personal frontline observations, all of which make it challenging to assimilate the study's implications: patients with COVID-19 are no different from a typical population with acute respiratory distress syndrome (ARDS), and, if managed with conventionally accepted ARDS ventilator strategies alone, a mortality rate under 17% is within reach. A closer look at certain features of the study invites skepticism:1. A total of 21/66 (34%) patients were treated with statins prior to hospital presentation, but that number ballooned to 54/66 (82%) during the study course. Though mechanistic plausibility exists ([@bib5]) and patients newly started on a statin may have been clinical trial participants, one is left wondering about a "standard" approach to ARDS management that includes a therapy shown to have no benefit in two major randomized clinical trials ([@bib6], [@bib7]).2. Informative is a juxtaposition of this patient sample with that of the PROSEVA (Proning Severe ARDS Patients) trial ([@bib8]), results of which have been widely applied to the care of patients with lung disease associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the assumption of a common pathobiology and therefore response to interventions. Fewer than half (47%) of patients underwent prone positioning in Ziehr and colleagues, and the median time for this intervention was Day 3. Despite this rate and timing of proning, Figure 1 of Reference 1 demonstrates that the initial median Pa~O2~:F[i]{.smallcaps}~O2~ ratio of 182 for the entire cohort on Day 1 was already up to a median of approximately 250 by Day 2, a time by which only the first quartile of the eventually proned patients had even begun proning as indicated by the interquartile range of 2--5. In contrast, after the first day, the proning arm of the PROSEVA trial---all of which was proned---exhibited a barely detectable improvement in Pa~O2~:F[i]{.smallcaps}~O2~ ratio measured in the supine position (Table S2 of Reference 8). Such "unARDS-like" clinical behavior casts a shadow over the conclusions of the study by Ziehr and colleagues.3. The authors report a tracheostomy rate of 21.2%. This figure far exceeds ARDS tracheostomy rates in a global sample (13%) ([@bib9]) and in the supine group of the PROSEVA trial (5.2%), study populations that are both characterized by greater ARDS severity than the cohort of Ziehr and colleagues. Tracheostomy has been shown to improve short-term but not long-term survival in patients with ARDS ([@bib9]).4. The authors registered an ICU discharge rate of 75.8%, a result that is discordant with other reports ([@bib2]) and enthusiasm about which warrants caution. A common frontline observation is that patients with COVID-19 are highly susceptible to complicated hospital courses following initial ICU discharge, punctuated by returns to the ICU and a remarkable propensity for sudden death. Data about this aspect of critical illness in COVID-19 are lacking, but the ICU discharge rate reported by Ziehr and colleagues risks conveying a prematurely optimistic message.

The arguments presented herein are a call for care in adopting the results of the study by Ziehr and colleagues as demonstration that SARS-CoV-2 lung disease fully conforms to the ARDS paradigm and as the latest benchmark for ICU outcomes in this condition. Frontline experience suggests that reality lies somewhere between published extremes.
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